Hypertensive Disorder — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypertensive disorder. 66 active patents protecting 10 drugs from 6+ originators. First major cliff: 2031. Daily refresh.

10
Approved drugs
66
Active US patents
53/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypertensive Disorder

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Searle/Pfizer) 25 patents Azurity 13 patents Chiesi 9 patents Lavipharm 4 patents Merck & Co. 2 patents King Pfizer 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypertensive disorder. Each bar = one year. Y-axis scaled to peak year (24 patents).

2
27
11
31
4
32
4
34
24
35
17
36
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vasotec
ENALAPRIL MALEATE
 Azurity 13 38 — 2032-11-06
Accutane
ISOTRETINOIN
 — 12 42 — 2035-05-29
Zestril
lisinopril
 Generic (originally Merck/AstraZeneca) 12 36 — 2035-11-06
Cleviprex
CLEVIDIPINE
 Chiesi 9 33 — 2031-10-10
Aldactone
spironolactone
 Generic (originally Searle/Pfizer) 8 50 — 2036-10-28
Lasix
furosemide
 Generic (originally Hoechst AG) 4 66 — 2034-04-03
Catapres-Tts-1
CLONIDINE
 Lavipharm 4 54 — 2027-04-17
Cozaar
LOSARTAN POTASSIUM
 Merck & Co. 2 65 — 2041-10-07
Microzide
hydrochlorothiazide
 Generic (originally Merck) 1 75 — 2044-01-23
Altace
RAMIPRIL
 King Pfizer 1 75 — 2039-08-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12370168 Lasix method of use 75 2034-04-03
12343338 Altace method of use 75 2039-08-16
12156869 Cozaar method of use 75 2041-10-07
11878022 Microzide method of use 75 2044-01-23
11433044 Lasix method of use 70 2034-04-03
9884039 Lasix method of use 70 2034-04-03
11395828 Aldactone method of use 70 2036-10-28
9757394 Aldactone method of use 62 2036-10-28
8337890 Catapres-Tts-1 formulation 60 2027-04-17
8337890 Catapres-Tts-1 formulation 60 2027-04-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9463183 Zestril formulation 25 2035-11-06
9814751 Zestril formulation 25 2035-11-06
10265370 Zestril formulation 25 2035-11-06
11179434 Zestril formulation 25 2035-11-06
10940177 Zestril formulation 25 2035-11-06
11040023 Vasotec formulation 30 2036-03-25
10786482 Vasotec formulation 30 2036-03-25
10039745 Vasotec formulation 30 2036-03-25
11141405 Vasotec formulation 30 2036-03-25
9669008 Vasotec formulation 30 2036-03-25

Related